Conference Correspondent

Conference Correspondent

The following summaries represent a sample of the many real-world, evidence-based studies presented at the 29th Annual Meeting of the Academy of Managed Care Pharmacy (AMCP), March 27-30, 2017, in Denver, CO.
Washington, DC—With tremendous changes occurring in healthcare and particularly in oncology, discussion about the current trends and demands facing stakeholders in optimizing value in cancer care dominated the Sixth Annual Conference of the Association for Value-Based Cancer Care, held September 27-29, 2016, and co-chaired by Michael Kolodziej, MD, National Medical Director, Managed Care Strategy, Flatiron Health, New York, NY; and Burt Zweigenhaft, BS, President, National Association of Specialty Pharmacy; and Editor-in-Chief, Value-Based Cancer Care.

In this analysis, researchers evaluate whether daratumumab can further reduce minimal residual disease when added to lenalidomide- and bortezomib-containing regimens in patients with relapsed/refractory multiple myeloma.

Researchers conducted a systematic literature review and subsequent meta-analysis of progression-free survival outcomes to compare 16 different treatment regimens for relapsed/refractory multiple myeloma.

In an effort to determine whether lower peripheral neuropathy rates could be achieved, this study evaluated the efficacy and safety of subcutaneous bortezomib in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma.

Payers have expressed concern about the rising costs of combination therapies in multiple myeloma. In an effort to address these potential concerns, a budget impact model was developed to estimate the 3-year costs of adding elotuzumab in combination with lenalidomide and dexamethasone to a health plan’s formulary.

Risk stratification tools are used to estimate survival expectations and help to guide treatment decisions after first relapse in multiple myeloma. European researchers have developed a new stratification tool consisting of 4 distinct dimensions that are used to characterize risk of survival.

Immunotherapy is being studied as a potential treatment approach in a variety of hematologic malignancies. Here, researchers present the findings of a phase 2 trial evaluating pembrolizumab in combination with pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma.

Unmet treatment needs remain in multiple myeloma, particularly among patients with relapsed/refractory disease who have received multiple lines of therapy. This study evaluates a potential salvage approach of daratumumab-based retreatment in patients refractory to daratumumab and/or pomalidomide.

PREAMBLE (Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation) is an ongoing multinational observational study being conducted to evaluate real-world outcomes in patients with multiple myeloma. Here, researchers present preliminary efficacy analyses in patients with one line of prior therapy.

Page 1 of 6
Results 1 - 10 of 56
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • National Association of Specialty Pharmacy
  • Lynx CME